TREA

99061671 - RUTHINIUM

Follow

Information

  • Trademark
  • 99061671
  • Serial Number
    99061671
  • Filing Date
    February 28, 2025
    a year ago
  • Transaction Date
    July 02, 2025
    10 months ago
  • Status Date
    July 01, 2025
    10 months ago
  • Location Date
    July 01, 2025
    10 months ago
  • Status Code
    641
  • Current Location
    TMO LAW OFFICE 133
    Employee Name
    SULLIVAN,JOHN C
  • Attorney Docket Number
    VAND-0194-US
    Attorney Name
    Jayme M Torelli
    Law Office Assigned Location Code
    O60
  • Owners
Information
Mark Drawing Code
4
Mark Identification
RUTHINIUM
Case File Statements
  • GS0051: Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of bile acid diarrhea; Pharmaceutical preparations for the treatment of tyrosine kinase inhibitor (TKI)-induced diarrhea; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of COVID-19; Pharmaceutical preparations for the treatment of inflammatory lung injury (ILI); Pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS); Pharmaceutical preparations for the treatment of social anxiety disorder; Pharmaceutical preparations for the treatment of performance anxiety; Pharmaceutical preparations for the treatment of public speaking anxiety; Pharmaceutical preparations for the treatment of circadian rhythm disorders; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of insomnia; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder; Pharmaceutical preparations for the treatment of non-24 hour sleep-wake disorder; Pharmaceutical preparations for the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations for the treatment of nighttime sleep disturbances in patients with Smith-Magenis Syndrome; Pharmaceutical preparations for the treatment of major depressive disorder; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of multiple myeloma; Pharmaceutical preparations for the treatment of Charcot-Marie-Tooth disease; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of cravings for opioid substances or opiate substances; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of the neuropeptide known as substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor
Case File Event Statements
  • 2/28/2025 - a year ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 2/28/2025 - a year ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 6/24/2025 - 11 months ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 7/1/2025 - 10 months ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 7/1/2025 - 10 months ago
    6 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 7/1/2025 - 10 months ago
    7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 2/28/2025 - a year ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR